Government orders 660m doses amid jab shortage
SEVERAL STATES REPORT SCARCITY, WITH MANY INOCULATION CENTRES SHUT
The Indian government has ordered 660 million vaccine doses for August-December, its largest procurement, local news reports said yesterday, as state authorities and health experts warned that shortages could leave millions vulnerable if coronavirus infections surge again.
The federal government aims to inoculate all of the country’s estimated 944 million adults by December, a target health experts have said is ambitious, as only 8 per cent of that number is currently vaccinated with the mandatory two doses.
Several states have reported vaccine shortages, with many inoculation centres shut and people having to wait for long hours at others for their shot.
Local supply
The government has now ordered 375 million more doses of AstraZeneca’s locally produced Covishield and 285 million doses of Bharat Biotech’s homegrown Covaxin, the Economic Times newspaper reported, citing sources.
The health ministry did not immediately respond to a Reuters request for comment.
The Serum Institute of India, which manufactures Covishield, has raised monthly production to about 100 million doses.
The government says Bharat Biotech’s monthly output will jump to as much as 70 million doses in July/August, from about 10 million doses in April. Production could rise further to nearly 100 million by September, it says.
Bharat Biotech, which has been struggling to raise output of its vaccine, did not respond to a request for an update on its production plans.
“I expect the vaccine shortage to continue and as per the planned vaccine supply, it appears that the daily average for the whole of July will stay below 4 million,” said Rijo John, health economist and a professor at the Rajagiri College of Social Sciences in the southern city of Kochi.
Big dip
After a record 9.1 million doses were administered on June 21, fewer than 4 million doses per day have since been given on an average this month.
A full roll-out of Russia’s Sputnik V vaccine in India has also been delayed due to a lack of imported supplies. Commercial production of the vaccine in India, however, could begin soon.
India’s daily Covid-19 cases have dropped to nearly twomonth lows, the country remains the second-highest globally in terms of daily infections.